-
Jeanette posted an update in the group WeHeal Lymphoma Advocate Network
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy | Business WireKite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta&trade
-
Aarchi Advani joined the group WeHeal Lymphoma Advocate Network
-
Daniel Christian Patient Advocate joined the group WeHeal Lymphoma Advocate Network
-
Richard joined the group WeHeal Lymphoma Advocate Network
-
Justo Pulido joined the group WeHeal Lymphoma Advocate Network
-
Jeanette posted an update in the group WeHeal Lymphoma Advocate Network
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy | Business WireKite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta&trade-
Yeah! Immune Therapies are here!
-
-
Jeanette joined the group WeHeal Lymphoma Advocate Network
-
Miyoko joined the group WeHeal Lymphoma Advocate Network
-
Ericdrew18 joined the group WeHeal Lymphoma Advocate Network
-
Eric Drew joined the group WeHeal Lymphoma Advocate Network
-
WeHeal created the group WeHeal Lymphoma Advocate Network
Yeah! Immune Therapies are here!